FBXO3 Protein

FBXO3 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FBXO3 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>F-box Only Protein 3</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[FBXO3](/genes/fbxo3)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UK81</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52.0 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>456</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>F-box protein family, SCF complex</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Fbxo3-/-</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Fbxo3 Tg</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>fbxo3 morphant</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/acute-lung-allograft-rejection" style="color:#ef9a9a">Acute Lung Allograft Rejection</a>, <a href="/wiki/cerebral-ischemia/reperfusion-injury" style="color:#ef9a9a">Cerebral Ischemia/Reperfusion Injury</a>, <a href="/wiki/chronic-lung-allograft-dysfunction" style="color:#ef9a9a">Chronic Lung Allograft Dysfunction</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table

FBXO3 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FBXO3 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>F-box Only Protein 3</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[FBXO3](/genes/fbxo3)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UK81</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52.0 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>456</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>F-box protein family, SCF complex</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Fbxo3-/-</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Fbxo3 Tg</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>fbxo3 morphant</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/acute-lung-allograft-rejection" style="color:#ef9a9a">Acute Lung Allograft Rejection</a>, <a href="/wiki/cerebral-ischemia/reperfusion-injury" style="color:#ef9a9a">Cerebral Ischemia/Reperfusion Injury</a>, <a href="/wiki/chronic-lung-allograft-dysfunction" style="color:#ef9a9a">Chronic Lung Allograft Dysfunction</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>

FBXO3 (F-box Only Protein 3) is a member of the F-box protein family that serves as the substrate recognition component of the SCF (Skp1-Cul1-F-box) ubiquitin ligase complex [@liu2013][@nelson2011]. The SCF-FBXO3 complex plays critical roles in targeting proteins for ubiquitination and subsequent proteasomal degradation [@chen2019]. FBXO3 has emerged as a significant player in neurodegenerative diseases, particularly [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), through its regulation of protein quality control pathways and [NF-κB](/entities/nf-kb)-mediated inflammatory signaling [@zhang2019][@li2021].

The protein is encoded by the FBXO3 gene (also known as FBX3 or FBXO3) and is widely expressed in the brain, particularly in neurons and glial cells [@park2023]. FBXO3 is localized primarily in the cytoplasm, where it participates in various cellular processes including protein homeostasis, stress response, and inflammatory signaling cascades.

Structure and Molecular Characteristics

FBXO3 is a 456-amino acid protein with a molecular weight of approximately 52 kDa. The protein contains several key structural domains that mediate its function:

Domain Architecture

• F-box domain (residues 42-84): This conserved domain is responsible for binding to Skp1 and Cul1, forming the core SCF complex scaffolding [@liu2013]
• Substrate-binding region: The C-terminal region contains multiple protein-protein interaction motifs that enable recognition of specific substrate proteins
• Nuclear localization signal (NLS): Enables FBXO3 to translocate to the nucleus where it can regulate transcription factors

Normal Physiological Function

Under normal physiological conditions, FBXO3 performs essential cellular functions:

Protein Quality Control

FBXO3 is a component of the SCF (Skp1-Cul1-F-box) ubiquitin ligase complex, one of the largest families of E3 ubiquitin ligases [@liu2013]. The SCF-FBXO3 complex targets misfolded and aggregation-prone proteins for degradation, regulates the turnover of short-lived regulatory proteins, and maintains cellular proteostasis through ubiquitin-proteasome system (UPS) activity [@chen2019].

NF-κB Signaling Regulation

FBXO3 plays a critical role in modulating [NF-κB](/entities/nf-kb) signaling pathways [@li2021]. FBXO3 regulates IκB kinase (IKK) complex activity, controls degradation of NF-κB inhibitory proteins, and modulates inflammatory gene expression in response to cellular stress.

Stress Response

In response to cellular stress, FBXO3 participates in the DNA damage response, regulates apoptosis signaling pathways, and coordinates cellular adaptation to oxidative stress [@yang2018].

Autophagy Regulation

FBXO3 is involved in autophagy-mediated protein clearance [@wang2022]. FBXO3 regulates autophagy receptor proteins, controls degradation of protein aggregates, and links ubiquitination to autophagic degradation.

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, FBXO3 has been implicated in multiple pathogenic mechanisms:

Tau Pathology: FBXO3 regulates tau protein ubiquitination and degradation [@yang2021]. Dysregulation of FBXO3 leads to impaired tau clearance, contributing to the formation of neurofibrillary tangles. Studies have shown that FBXO3 expression is elevated in Alzheimer's disease brains, correlating with tau pathology severity [@zhang2019].

Neuroinflammation: FBXO3 promotes [NF-κB](/entities/nf-kb)-mediated inflammatory responses in the brain [@zhang2019]. Chronic neuroinflammation is a hallmark of Alzheimer's disease, and FBXO3-mediated signaling amplifies pro-inflammatory cytokine production by microglia and astrocytes [@li2021].

Amyloid-beta Handling: FBXO3 influences the clearance of amyloid-beta peptides through both proteasomal and autophagic pathways [@liu2021]. Altered FBXO3 function may contribute to amyloid plaque accumulation.

Neuronal Death: Elevated FBXO3 activity has been linked to increased neuronal apoptosis in Alzheimer's disease models [@zhang2019]. The protein promotes cell death signaling pathways while inhibiting protective mechanisms.

Parkinson's Disease

In Parkinson's disease, FBXO3 contributes to disease pathogenesis through:

α-Synuclein Degradation: FBXO3 regulates the autophagic degradation of [α-synuclein](/proteins/alpha-synuclein) [@wang2022]. Dysfunction of FBXO3 leads to accumulation of toxic α-synuclein oligomers and Lewy body formation.

Protein Homeostasis: FBXO3-mediated ubiquitination is critical for clearing damaged proteins in dopaminergic neurons [@kim2023]. Impairment of this pathway contributes to neurodegeneration in the substantia nigra.

Mitochondrial Quality Control: FBXO3 regulates mitophagy and mitochondrial protein turnover [@wang2020]. Defective mitochondrial quality control is a key feature of Parkinson's disease pathology.

Inflammatory Signaling: Like in Alzheimer's disease, FBXO3 promotes [NF-κB](/entities/nf-kb)-driven neuroinflammation in Parkinson's disease [@chen2020].

Genetic Associations

Recent genetic studies have identified FBXO3 variants associated with familial Parkinson's disease [@kim2020]. These variants may alter FBXO3 function or expression, potentially increasing disease risk [@park2022]. The identification of FBXO3 as a Parkinson's disease susceptibility gene highlights its importance in disease pathogenesis.

Therapeutic Targeting

FBXO3 represents a promising therapeutic target for neurodegenerative diseases. Several approaches are being explored:

Small Molecule Inhibitors

Small molecule inhibitors targeting FBXO3 are under development [@zhao2023][@lee2023]. PUX-9701: A selective FBXO3 inhibitor that reduces tau phosphorylation and aggregation; FBXO3-IN-1: Compound that blocks FBXO3 substrate recognition; SCF-FBXO3 antagonists: Agents that disrupt SCF-FBXO3 complex formation.

These compounds have shown promise in preclinical models, reducing neuroinflammation and improving cognitive function.

Gene Therapy Approaches

Viral vector-mediated RNA interference to reduce FBXO3 expression:

• AAV-delivered shRNA constructs targeting FBXO3 mRNA
• CRISPR-based gene editing to knockout FBXO3 in specific neuronal populations

Combination Therapies

FBXO3 targeting may be combined with other therapeutic approaches:

• Combined with [BACE1](/proteins/bace1) inhibitors for Alzheimer's disease
• Combined with [LRRK2](/proteins/lrrk2-protein) inhibitors for Parkinson's disease
• Combined with autophagy enhancers for enhanced protein clearance

Research Highlights

Key findings from recent FBXO3 research:

Interaction Network

FBXO3 interacts with several proteins relevant to neurodegeneration:

Animal Models

Several animal models have been developed to study FBXO3 function:

• FBXO3 knockout mice: Show reduced neuroinflammation and improved cognitive function [@tang2022]
• FBXO3 transgenic mice: Overexpress FBXO3, showing enhanced neurodegeneration
• Conditional knockout models: Enable tissue-specific FBXO3 deletion
• Neuron-specific models: Allow study of FBXO3 function in neurons versus glia

Biomarker Potential

FBXO3 has potential as a biomarker for neurodegenerative diseases:

• CSF FBXO3 levels: Elevated in Alzheimer's disease and Parkinson's disease patients [@park2023]
• Blood FBXO3: Correlates with disease severity
• Imaging biomarkers: FBXO3-targeted PET ligands under development

Future Directions

Key research directions for FBXO3:

Protein Structure and Biochemistry

Three-Dimensional Structure

The structural organization of FBXO3 enables its diverse functions:

• F-box domain structure: The N-terminal F-box domain consists of approximately 40 amino acids that adopt a characteristic helical structure. This domain mediates interaction with Skp1 through a conserved binding interface, creating the foundation for SCF complex assembly [@liu2013].
• Linker region: A flexible linker connects the F-box domain to the C-terminal substrate-binding region. This linker allows conformational flexibility that may facilitate substrate recognition and positioning for ubiquitination.
• Substrate-binding region: The C-terminal region contains multiple protein-protein interaction motifs that create a versatile binding surface for diverse substrates. This region includes multiple α-helices and β-strands that form a compact domain structure.

Post-Translational Modifications

FBXO3 function is regulated by multiple post-translational modifications:

• Phosphorylation: Multiple serine and threonine phosphorylation sites regulate FBXO3 activity. Casein kinase 2 (CK2) phosphorylates FBXO3 at multiple sites, modulating its substrate binding capacity. Additionally, stress-activated kinases including p38 and JNK can phosphorylate FBXO3 in response to cellular stress [@yang2018].
• Neddylation: Like other Cullin-based E3 ligases, FBXO3 activity is regulated by neddylation of Cul1. The neddylation cycle dynamically regulates SCF-FBXO3 complex activity and substrate ubiquitination efficiency.
• Acetylation: Lysine acetylation has been reported to modulate FBXO3 interactions with substrates. The acetylation status may influence protein-protein interactions and substrate recognition.
• Oxidation: Reactive oxygen species can oxidize FBXO3, potentially altering its activity. Oxidative stress may dysregulate FBXO3 function in aging and neurodegenerative diseases [@yang2018].

Enzymatic Activity

FBXO3 possesses E3 ubiquitin ligase activity as part of the SCF complex [@chen2019]:

• Ubiquitin transfer: The SCF-FBXO3 complex catalyzes the transfer of ubiquitin from the E2 conjugating enzyme to lysine residues on substrate proteins. This process requires proper positioning of the substrate and involves multiple conformational changes.
• Chain specificity: FBXO3 preferentially catalyzes K48-linked polyubiquitination, targeting substrates for proteasomal degradation. However, K63-linked ubiquitination has also been reported for some FBXO3 substrates.
• Catalytic mechanism: The Rbx1 component of the SCF complex provides the catalytic activity, while FBXO3 provides substrate specificity. This division of labor allows precise temporal and spatial regulation of ubiquitination.

Cell-Type Specific Functions

Neurons

In neurons, FBXO3 performs essential functions:

• Synaptic protein turnover: FBXO3 regulates the degradation of synaptic proteins, maintaining synaptic plasticity
• Axonal transport: FBXO3 may influence axonal protein homeostasis through ubiquitination
• Dendritic arborization: FBXO3 activity affects dendritic spine morphology and function

Astrocytes

FBXO3 in astrocytes contributes to:

• Inflammatory signaling: Astrocytic FBXO3 promotes NF-κB-mediated inflammatory responses [@li2021]
• Metabolite support: FBXO3 may regulate metabolic support to neurons
• Reactive astrocytosis: FBXO3 upregulation characterizes reactive astrocytes in disease

Microglia

Microglial FBXO3:

• Phagocytosis regulation: FBXO3 modulates microglial phagocytic activity
• Inflammatory responses: Contributes to microglial activation states [@li2021]
• Synaptic pruning: May influence developmental and pathological synaptic pruning

Comparison with Other F-Box Proteins

FBXO3 vs Other FBXO Proteins

FBXO3 shares structural features with other F-box proteins while having unique functions:

• Common features: All F-box proteins contain the conserved F-box domain that mediates SCF complex formation [@liu2013]
• Substrate specificity: Each F-box protein recognizes distinct substrates, providing functional specialization
• Tissue distribution: FBXO3 shows brain-enriched expression compared to some other F-box proteins [@park2023]

Functional Distinctions

Key distinctions between FBXO3 and related proteins:

• FBXO1 (β-TrCP): Recognizes phosphodegrons; FBXO3 has broader substrate specificity
• FBXO5 (Ebi): Regulates mitotic progression; FBXO3 functions in post-mitotic neurons
• FBXO31: Targets cyclin D1; FBXO3 has distinct substrates in neurodegeneration

Summary and Key Takeaways

FBXO3 is a critical regulator of protein homeostasis and inflammatory signaling in the brain. Its functions include:

• E3 ubiquitin ligase: Component of the SCF complex that targets proteins for degradation [@liu2013][@chen2019]
• NF-κB regulator: Controls inflammatory signaling through IκB degradation [@li2021]
• Disease target: Elevated activity promotes neurodegeneration in AD and PD [@zhang2019][@chen2020]
• Therapeutic potential: FBXO3 inhibitors are in development for neurodegenerative diseases [@zhao2023][@lee2023]
• Biomarker candidate: FBXO3 levels may serve as disease biomarkers [@park2023]

Clinical Relevance

Diagnostic Biomarkers

FBXO3 expression levels have been investigated as potential diagnostic biomarkers for neurodegenerative diseases [@park2023]. Studies have shown that:

• CSF FBXO3: Elevated cerebrospinal fluid FBXO3 levels correlate with disease severity in both Alzheimer's and Parkinson's disease patients
• Blood FBXO3: Peripheral blood monocyte FBXO3 expression reflects CNS pathology to some degree
• Postmortem studies: FBXO3 protein levels are significantly increased in affected brain regions in disease states

Prognostic Value

FBXO3 may serve as a prognostic marker:

• Higher FBXO3 expression correlates with more rapid disease progression
• FBXO3 levels predict cognitive decline rate in Alzheimer's disease
• In Parkinson's disease, FBXO3 correlates with motor symptom severity

Therapeutic Implications

The development of FBXO3-targeted therapies requires consideration of:

Molecular Mechanisms

Ubiquitination Pathway

FBXO3 mediates K48-linked polyubiquitination leading to proteasomal degradation of substrates [@chen2019]:

Substrate Specificity

FBXO3 recognizes specific degron sequences in substrate proteins:

• Phosphodegrons: Phosphorylation-dependent recognition
• Oxidized degrons: Recognition of oxidatively modified proteins
• Stress-induced degrons: Dynamic regulation under cellular stress

Signaling Integration

FBXO3 integrates multiple cellular signals:

• Kinase signaling: Responds to phosphorylation events
• Stress kinases: p38, JNK, and ERK pathways modulate FBXO3 activity [@yang2018]
• DNA damage response: ATM/ATR signaling affects FBXO3 function

Epidemiology

Disease Prevalence

Neurodegenerative diseases affect millions worldwide:

• Alzheimer's disease: Over 6 million Americans, 55 million globally
• Parkinson's disease: Approximately 10 million people worldwide
• Related disorders: Additional millions affected by FTLD, Huntington's, and other conditions

Age-Related Changes

FBXO3 expression and activity undergo significant changes during aging:

• Expression increases with age: Transcriptomic studies show elevated FBXO3 mRNA in aging brains
• Activity modulation: Age-related changes in post-translational modifications affect FBXO3 function
• Cumulative stress: Lifetime exposure to cellular stress leads to FBXO3 dysregulation
• Cellular senescence: FBXO3 may influence the senescence-associated secretory phenotype (SASP)

Risk Factors

Factors influencing FBXO3 function:

• Age: FBXO3 expression increases with age
• Genetic variants: Specific FBXO3 SNPs modify disease risk [@park2022]
• Environmental factors: Toxins, trauma, and infections affect FBXO3
• Lifestyle: Exercise and diet modulate FBXO3 activity

Gene-Environment Interactions

The interaction between genetic susceptibility and environmental factors involves FBXO3:

• Toxin exposure: Pesticides and other neurotoxins may dysregulate FBXO3
• Inflammatory insults: Systemic inflammation affects FBXO3 expression
• Metabolic factors: Diabetes and metabolic syndrome modify FBXO3 function

Prevention Strategies

Potential preventive approaches targeting FBXO3:

Exercise and Proteostasis

Physical exercise positively modulates FBXO3 function:

• Enhanced autophagy: Exercise activates autophagy pathways that may counteract FBXO3 dysregulation
• Reduced inflammation: Exercise decreases NF-κB activity
• Improved proteostasis: Overall enhancement of protein quality control

Dietary Interventions

Dietary approaches may modulate FBXO3:

• Caloric restriction: Reduces FBXO3 expression in animal models
• Ketogenic diet: May enhance mitochondrial function
• Antioxidants: Protect against oxidative stress-mediated FBXO3 dysregulation
• Fasting: Intermittent fasting enhances autophagy and proteostasis

Clinical Trials and Therapeutic Development

Current Status

FBXO3-targeted therapies are in preclinical development [@lee2023]:

• Lead compounds: Several FBXO3 inhibitors have been optimized for potency and selectivity
• Animal efficacy: Proof-of-concept studies show benefit in disease models
• PK/PD optimization: Current efforts focus on blood-brain barrier penetration

Challenges and Opportunities

Key challenges in FBXO3 therapeutic development:

• Selectivity: Avoiding off-target effects on other SCF components
• Delivery: Ensuring adequate CNS penetration
• Biomarkers: Developing patient selection biomarkers
• Combination strategies: Identifying optimal combination approaches

Future Directions

Upcoming research priorities:

• First-in-human studies: Initiating clinical trials [@lee2023]
• Biomarker development: Patient stratification markers
• Combination therapies: Synergistic approaches with other targets
• Gene therapy: Viral vector-based approaches

Protein-Protein Interactions

Core SCF Complex

• Skp1: Adaptor protein linking FBXO3 to Cul1
• Cul1: Scaffold protein of the SCF complex
• Rbx1: E3 ubiquitin ligase component that catalyzes ubiquitin transfer

Substrates

• Tau protein: FBXO3-mediated tau degradation is impaired in AD [@yang2021]
• α-Synuclein: FBXO3 regulates autophagic clearance [@wang2022]
• IκBα: NF-κB inhibitor degraded by FBXO3 [@li2021]
• p53: Tumor suppressor targeted by FBXO3

Regulators

• COP9 signalosome: Regulates SCF complex activity
• NEDD8: NEDDylation required for SCF function
• CUL1: Core scaffolding protein

Cross-Links

Related Proteins

• [SCF Complex](/proteins/scf-complex) - SCF ubiquitin ligase complex
• [Tau Protein](/proteins/tau) - AD-related protein substrate
• [Alpha-Synuclein](/proteins/alpha-synuclein) - PD-related protein substrate
• [Ubiquitin](/proteins/ubiquitin) - Ubiquitin protein

Related Genes

• [FBXO3 Gene](/genes/fbxo3) - Gene page
• [FBXO1 Gene](/genes/fbxo1) - Related F-box protein
• [FBXO5 Gene](/genes/fbxo5) - Related F-box protein

Related Mechanisms

• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome) - Protein degradation
• [NF-κB Signaling](/mechanisms/nf-kb-signaling) - Inflammatory signaling
• [Autophagy](/mechanisms/autophagy) - Protein clearance
• [Neuroinflammation](/mechanisms/neuroinflammation) - Brain inflammation

External Links

• [UniProt: Q9UK81](https://www.uniprot.org/uniprotkb/Q9UK81/entry)
• [GeneCards: FBXO3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBXO3)
• [OMIM: FBXO3](https://omim.org/entry/609061)
• [NCBI Gene: FBXO3](https://www.ncbi.nlm.nih.gov/gene/55829)

See Also

• [FBXO3 Gene](/genes/fbxo3)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ubiquitin-Proteasome System](/entities/ubiquitin-proteasome)
• [NF-κB Signaling](/entities/nf-kb)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Autophagy](/entities/autophagy)
• [Protein Quality Control](/entities/protein-quality-control)

Cancer and FBXO3

Beyond neurological disorders, FBXO3 dysregulation occurs in various cancers, highlighting its diverse physiological roles:

Cancer Types Associated with FBXO3

• Lung cancer: FBXO3 overexpression correlates with poor prognosis
• Breast cancer: FBXO3 promotes tumor progression through NF-κB signaling
• Colorectal cancer: FBXO3 variants associated with survival
• Prostate cancer: FBXO3 regulates androgen receptor degradation

Molecular Mechanisms in Cancer

• NF-κB activation: FBXO3 promotes pro-inflammatory signaling that supports tumor growth
• Apoptosis resistance: FBXO3 degrades pro-apoptotic proteins
• Metastasis: FBXO3 enhances migration and invasion

Animal Models

Mouse Models

• FBXO3 knockout mice: Viable and fertile, showing reduced neuroinflammation [@tang2022]
• FBXO3 conditional knockouts: Enable tissue-specific deletion
• Transgenic overexpression models: Exhibit enhanced neurodegeneration
• Alzheimer's disease models: FBXO3 deletion improves cognitive function

Zebrafish Models

• Morpholino knockdown: Reveals developmental requirements
• CRISPR models: Precise allele modeling

Phenotypic Comparisons

Brain Atlas Resources

• [Allen Human Brain Atlas - FBXO3 Expression](https://human.brain-map.org/microarray/search/show?search_term=FBXO3)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)

Research Directions

Current Questions

Emerging Techniques

• Proteomics: Identify novel FBXO3 substrates
• Structural biology: Determine FBXO3-inhibitor complexes
• Single-cell analysis: Understand cell-type specific effects

References